Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
8.6
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPNet Sales362,210Millions of yenYear on year +8.6%Progress 48.9%
Operating profit8,593Millions of yenYear on year +4.4%Progress 33.1%
Ordinary income9,533Millions of yenYear on year +8.6%Progress 36.0%
Net income attributable to owners of the parent6,130Millions of yenYear on year +12.1%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥67.07
Financial position at period-end
Total assets374,120Millions of yen
of which net assets 148,598 Millions of yenEquity ratio 39.5%vs. prior year-end +0.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+12,807
Investment-2,089
Financials-10,980
Net change-262
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period78,326 Millions of yen
Segment revenueTotal Pack Produce Business 59,432 Millions of yen (YoY +16.1%), Medical Supply Business 267,371 Millions of yen (YoY +8.4%), Life Care Business 18,012 Millions of yen (YoY -2.9%), Dispensing Pharmacy Business 17,393 Millions of yen (YoY +2.7%)
Segment profitTotal Pack Produce Business 3,003 Millions of yen (YoY +21.6%), Medical Supply Business 3,064 Millions of yen (YoY +8.1%), Life Care Business 931 Millions of yen (YoY -8.4%), Dispensing Pharmacy Business 1,710 Millions of yen (YoY -13.4%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales740,000 Millions of yen (YoY +3.0%)
Operating profit26,000 Millions of yen (YoY +6.2%)
Ordinary income26,500 Millions of yen (YoY +0.6%)
Profit attributable to owners of the parent16,000 Millions of yen (YoY +19.5%)
Revision to Earnings ForecastNone
Annual Dividend Forecast60 Yen → 65 Yen
Factors Behind Changes in Business Performance
Recognition of large-scale project contracts, the start of operations at newly contracted SPD (supply, processing and distribution) facilities, expansion of contracted service areas at existing facilities, and increases in cases handled in specialty areas and transaction volume. On the other hand, higher prices for goods and services, labor costs, pharmaceuticals and medical supplies, and logistics, as well as contract terminations resulting from some customers bringing meal provision in-house, were factors reducing profit.
Disclosure regarding the going concern assumption
Not applicable
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 1 / Company name ㈱MYNS / Excluded Number of companies 1 / Company name デルフィア Co., Ltd. (absorbed in merger by シップヘルスケアファーマシー Co., Ltd.)
Material subsequent eventsAt a meeting of the Board of Directors held on 6 November 2026, the company resolved to conduct a tender offer aimed at making CHARM CARE CORPORATION a wholly owned subsidiary, and commenced the tender offer on 9 November.
Impairment lossNone applicable (material impairment losses on fixed assets)
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets 12 Millions of yen, Other 0 Millions of yen / Extraordinary loss Loss on disposal of non-current assets 68 Millions of yen, Business structure improvement expenses 26 Millions of yen, Other 0 Millions of yen
Depreciation and amortization2,788 Millions of yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End94,350,134
Treasury Shares at Period-End4,090,400
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | 362,210 Millions of yen (YoY +8.6%) |
| Operating profit | 8,593 Millions of yen (YoY +4.4%) |
| Ordinary income | 9,533 Millions of yen (YoY +8.6%) |
| Profit attributable to owners of the parent | 6,130 Millions of yen (YoY +12.1%) |
| Net income per share | ¥67.07 |
| Equity ratio | End of the current fiscal period 39.5 / End of previous period 39.2 |
| Total assets | 374,120 Millions of yen |
| Net assets | 148,598 Millions of yen |
| Cash flows from operating activities | 12,807 Millions of yen |
| Cash flows from investing activities | -2,089 Millions of yen |
| Cash flows from financing activities | -10,980 Millions of yen |
| Cash and cash equivalents at end of period | 78,326 Millions of yen |
| Full-year earnings forecast | Net Sales 740,000 Millions of yen (YoY +3.0%) / Operating profit 26,000 Millions of yen (YoY +6.2%) / Ordinary income 26,500 Millions of yen (YoY +0.6%) / Profit attributable to owners of the parent 16,000 Millions of yen (YoY +19.5%) |
| Revision to Earnings Forecast | None |
| Annual Dividend Forecast | 60 Yen → 65 Yen |
| Segment revenue | Total Pack Produce Business 59,432 Millions of yen (YoY +16.1%), Medical Supply Business 267,371 Millions of yen (YoY +8.4%), Life Care Business 18,012 Millions of yen (YoY -2.9%), Dispensing Pharmacy Business 17,393 Millions of yen (YoY +2.7%) |
| Segment profit | Total Pack Produce Business 3,003 Millions of yen (YoY +21.6%), Medical Supply Business 3,064 Millions of yen (YoY +8.1%), Life Care Business 931 Millions of yen (YoY -8.4%), Dispensing Pharmacy Business 1,710 Millions of yen (YoY -13.4%) |
| Depreciation and amortization | 2,788 Millions of yen |
| Impairment loss | None applicable (material impairment losses on fixed assets) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 12 Millions of yen, Other 0 Millions of yen / Extraordinary loss Loss on disposal of non-current assets 68 Millions of yen, Business structure improvement expenses 26 Millions of yen, Other 0 Millions of yen |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name ㈱MYNS / Excluded Number of companies 1 / Company name デルフィア Co., Ltd. (absorbed in merger by シップヘルスケアファーマシー Co., Ltd.) |
| Material subsequent events | At a meeting of the Board of Directors held on 6 November 2026, the company resolved to conduct a tender offer aimed at making CHARM CARE CORPORATION a wholly owned subsidiary, and commenced the tender offer on 9 November. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 94,350,134 |
| Treasury Shares at Period-End | 4,090,400 |
| Factors Behind Changes in Business Performance | Recognition of large-scale project contracts, the start of operations at newly contracted SPD (supply, processing and distribution) facilities, expansion of contracted service areas at existing facilities, and increases in cases handled in specialty areas and transaction volume. On the other hand, higher prices for goods and services, labor costs, pharmaceuticals and medical supplies, and logistics, as well as contract terminations resulting from some customers bringing meal provision in-house, were factors reducing profit. |
Items this document does not state (5)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Overall consolidated results progressed broadly in line with the initial plan, supported by the recognition of large-scale project contracts, the start of operations at newly contracted SPD (supply, processing and distribution) facilities, and the expansion of contracted service areas at existing facilities. On the other hand, taxes and dues increased as the scope of companies subject to pro forma standard taxation was expanded.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.